Croda International‘s dividend yield has reached 3.7%, a level far above its decade average of 1.5%, as the speciality chemicals group’s shares sit 70% below their 2021 peak. The stock is attracting fresh attention from investors building income portfolios one month at a time.
The case for steady, index-level compounding alongside individual income stocks is straightforward enough. Investing £100 a month into a FTSE 100 tracker at the index’s annualised total return of around 6.9% since its 1984 inception produces, over 30 years, a portfolio worth roughly £119,617. Of that, just £36,000 represents contributions; the rest is compounded growth and reinvested dividends.
At 6.9% on the final portfolio value, that position would generate approximately £8,254 a year in income, without ever increasing the monthly contribution. Note that the FTSE 100’s return figure varies by measurement period: IG data puts the annualised total return for the 1984–2019 period at 7.75%, while a 20-year window from 2003 to 2023 produced 6.3% annually, according to IG’s historical analysis. The 6.9% figure used here reflects the original long-run estimate from inception; investors should treat any projection as illustrative rather than guaranteed.
The UK market also remains cheaply priced against global peers. The FTSE 100 trades at a forward price-to-earnings (P/E) ratio of around 13.4, against roughly 20 for the S&P 500. A heavier technology weighting drives part of that US premium, but the gap is wide by historical standards.
Croda International Dividend Yield in Context
For investors selecting individual UK income stocks, Croda International (LSE: CRDA) illustrates both the opportunity and the moving parts involved. The current yield of 3.7% is more than twice the average of the past decade, and it is rising for a specific reason: the share price has fallen sharply, not because the company has cut its dividend.
Croda declared an ordinary full-year dividend of 110.0p for 2024, up from 109.0p in 2023, according to the full-year 2024 results announcement. For full-year 2025, the company raised the dividend again to 111p, according to the FY2025 results and financial framework. The payout ratio has risen to 76%, above Croda’s stated policy range of 40–50% of adjusted earnings, which reflects earnings pressure rather than a decision to rebase income payments upward.
The earnings backdrop is under strain. Full-year 2024 group sales fell to £1,628.1m from £1,694.5m in 2023, a 3.9% decline on a reported basis. Adjusted profit before tax dropped to £260.0m from £308.8m. The FY2025 results included £107.3m in impairment charges and a further £44.6m related to optimising lipids manufacturing capacity.
What the Results Show
The earnings weakness does not spread evenly across Croda’s divisions. Consumer Care, the group’s largest segment, grew full-year 2024 sales to £920.0m from £886.1m in 2023, a 4% increase on a reported basis or 7% at constant currency, driven by an 11% rise in sales volumes, according to the Croda Annual Report 2024.
New and protected products, a measure of innovation pipeline productivity, grew 11% at constant currency in 2024 and accounted for 43% of total sales, up from 42% the prior year. That share matters because products specified into customer formulations are harder to switch out: re-testing and re-approval costs make price-driven substitution rare.
The lipids business remains the key swing factor. Demand has been recovering, but the US regulatory environment represents an active source of risk in the near term. Net debt was £532.3m at end of 2024, falling to £523.8m by end of 2025, with leverage declining to 1.3x, per the FY2025 document.
On valuation, Yahoo Finance shows a forward P/E of 16.86 for CRDA (data as of the date retrieved, subject to change). That is a meaningful discount to the S&P 500’s multiple, though still above the FTSE 100 average, and sits against a backdrop of impairment charges and a payout ratio the company itself acknowledges is above its target band.
The Croda International dividend yield’s persistence through two years of earnings declines signals financial discipline, but the payout ratio trajectory and the unresolved lipids regulatory position are the variables to monitor ahead of the next set of interim results. If earnings recover, the ratio normalises and the current income looks durable; if not, the company faces a harder conversation about its dividend policy.